coq10

Glioblastoma

Seema NagpalSmall moleculePhase 1Dormant

CC

40/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 65/ 100

Competitive context

234 Active assets in the Glioblastoma cohort.

Asset / Sponsor	Phase	Rating
Irinotecan University of Cincinnati	Phase 3	BB
(+)-VINCRISTINE University of Cincinnati	Phase 3	BB
Lomustine Telix Pharmaceuticals (Innovations) Pty Limited	Phase 3	BB
Enzastaurin Denovo Biopharma LLC	Phase 3	BB
ETOPOSIDE Sichuan Honghe Biotechnology Co., Ltd.	Phase 2/3	BB

View all 50 →

Same molecule, other indications

coq10 is also rated in:

Huntington diseaseDormant

B

Indicative ·

62 / 100

Duchenne muscular dystrophyDormant

B

Indicative ·

62 / 100

Becker muscular dystrophyDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.